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Abstract
Background: In this study, we prospectively evaluate the diagnostic potential of a gallium-68 (68Ga) prostate-
specific membrane antigen (PSMA)-binding ligand and positron emission tomography (PET) in detecting metastatic
lesions in patients with renal tumour. The secondary aim was to determine whether the findings would result in
the alteration of patient management.
Results: Ten patients with renal lesion and potential metastatic disease on conventional imaging were
recruited. Patients underwent PSMA PET in addition to standard imaging. Nine patients underwent
nephrectomy and 4 patients underwent additional targeted biopsy to provide specimens for histopathological
validation. There were 89 pathological lesions on CT, of which 32 were removed or biopsied for
histopathological correlation. With PSMA PET, 86 PET avid lesions were identified with 36 samples being
available for analysis. Thirty-five of 36 samples were positive for renal cell carcinoma deposits, whilst 1 sample
was inconclusive for diagnosis on biopsy. For the histologically confirmed lesions, there were no false-negative
PSMA PET lesions; however, CT was false negative in 11. In two patients, surgical strategies were changed based
on PSMA PET findings.
Conclusions: PSMA PET may potentially have a role in the preoperative staging of advanced renal cell
carcinoma as PET detected multiple histologically proven metastatic lesions which were false negative on CT
scanning, resulting in change in surgical strategies in some patients. We cautiously support a larger study to
confirm these results and to assess the longitudinal impact on patient outcomes.
Trial registration: Australia and New Zealand Clinical Trial Registry (ANZCTR), ACTRN12615000854538.
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Background
Kidney cancer is the sixth most common cancer in men
and the 11th most common cancer in women in
Australia. In 2014, metastatic renal cell carcinoma
(RCC) accounted for approximately 2 % of cancer death
[1]. Patients who are diagnosed with localized disease
are usually offered radical or partial nephrectomy. Un-
fortunately, depending on the tumour characteristics
such as histologic type, nucleolar grade, stage and ad-
verse pathological features, up to 50 % of patients with
clinically localized disease will develop metastasis during
follow-up [2, 3]. In patients later diagnosed with meta-
static disease, prognosis is poor with 5-year survival rate
below 10–20 % [4, 5].
During the initial staging, TNM classification by the
American Joint Committee on Cancer (AJCC) is used to
define metastatic disease [3]. Using these criteria, in
early phases of metastatic disease, neither computed
tomography (CT) nor bone scan (BS) is sensitive in de-
tecting small metastatic lesions [6]. There is a significant
clinical need for the development of more sensitive and
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specific imaging technology to detect metastatic foci that
could lead to early treatment and potential cure in true
oligometastatic settings. Magnetic resonance imaging has
been used to help further characterize renal tumours,
tumour extension, locoregional lymph nodes and meta-
static disease, although it is not used routinely [7].
Positron emission tomography (PET) is a technology
that may improve metastasis detection and challenge the
size criteria used for determining metastatic nodal in-
volvement by conventional imaging. PET can be used to
locate lesions with particular metabolic parameters or
expression of specific surface markers. For example,
fluorodeoxyglucose (FDG) has been used for staging,
prognostication and follow-up [8, 9]. It has previously
been demonstrated that a type II integral membrane
glycoprotein highly expressed in prostate cancer cells
called ‘prostate-specific membrane antigen’ (PSMA) is
also up-regulated in the neovasculature of solid tumours
including RCC [10]. For clear cell RCC, the reported
PSMA expression ranges from 80 to 100 %, whilst in other
carcinoma types such as chromophobe and papillary, the
expression is not as common (30–60 and 0 %, respect-
ively) [10–13]. Recently, Rowe et al. and Gorin et al.
demonstrated promising PET results with a novel PSMA-
binding ligand, 18F-DCFPyL, for detection of metastatic
renal cell carcinoma [14, 15]. A recent case report also
demonstrated significant improvement in staging meta-
static clear cell RCC using another novel PSMA-binding
ligand gallium-68 (68Ga)-PSMA-HBED-CC, over FDG
PET or CT imaging [16].
In this study, we prospectively evaluate the diagnostic po-
tential of PET using 68Ga-PSMA-HBED-CC (PSMA PET)
in detecting metastatic lesions in patients with renal tu-
mours with the secondary aim of determining whether the
findings will result in the alteration of treatment decisions.
Methods
Study design and population
Following ethical clearance, a phase I pilot clinical
trial was conducted (Ethics Approval Number: HREC/
15/QPAH/292, http://www.anzctr.org.au/default.aspx:
ACTRN12615000854538). All patients provided in-
formed consent prior to enrolment. Ten consecutive pa-
tients (n = 10) newly diagnosed with renal tumour and
suspicion for metastatic disease on standard imaging were
recruited into the trial. Patients were considered to harbour
metastatic lesions according to RECIST criteria 1.1: Mea-
surable lesions defined as lymph nodes greater than or equal
to 10 mm in short axis, or tumour lesions with minimum
size of 10 mm by CT scan, or 20 mm by chest X-ray [17].
Those who were unable to lie flat and had prior history of
other malignancies within the last 2 years, end-stage renal
failure or on haemodialysis were excluded from the study.
Standard imaging
In all patients, the primary renal tumour was identified
on computed tomography. Magnetic resonance imaging
(MRI), ultrasound (US) and bone scan (BS) were avail-
able in some cases for correlation. CT images were
performed on either Siemens Somatom Definition Flash
(2 × 192 slices) or Philips Brilliance iCT (256 slices). An
experienced uro-radiologist reported the imaging find-
ings prior to surgery and was blinded to the results of
the PSMA PET images. Patients were reported and
staged according to TNM staging and RECIST 1.1 cri-
teria [17]. Two patients were unable to receive iodine
contrast due to renal impairment, and one was allergic
to gadolinium for MRI.
PSMA PET
PSMA PET was performed within 4 weeks (median
delay = 3 weeks, range 1–4 weeks) of obtaining standard
imaging. 68Ga-PSMA-HBED-CC (HBED-CC, ABX AG,
Germany), also known as 68Ga-PSMA-11, was manufac-
tured at the Specialised PET Services Queensland Radio-
pharmaceutical laboratory as per Eder et al. [18]. PET
images were acquired 60 min after administration of
150 MBq ± 5 % of 68Ga-PSMA-HBED-CC for 3 min per
bed position on a Siemens Biograph mCT FLOW PET/
CT scanner. Iterative PET image reconstruction was per-
formed using 21 subsets, 3 iterations and matrix size of
200. A low-dose computed tomography (CT) scan was
performed with the PET scan for anatomic localisation
and attenuation correction. Combined PET/CT images
were read by an experienced nuclear medicine physician.
Lesions of interest were considered positive by qualita-
tive visual assessment, where avidity was greater than
background in areas without physiological uptake. For
example, a small lymph node with PET avidity greater
than 1.5 times greater than background was recorded as
pathological regardless of its size.
Histopathologic analysis
Ex-vivo histopathologic analysis was independently
performed by a single experienced uropathologist. The
resected samples were formalin-fixed and paraffin-
embedded into tissue blocks. Tissue slides were cut from
the blocks and stained with haematoxylin and eosin for
histopathologic evaluation.
Surgery
Of ten patients, nine patients underwent radical neph-
rectomy with removal of regional lymph nodes and
putative malignant lesions. One patient was found to be
not suitable for surgery due to obstructed superior vena
cava from large mediastinal nodes. Operations were per-
formed by three experienced urological surgeons who
were guided by conventional imaging and PSMA PET.
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Statistical analysis
The radiologist, the nuclear medicine physician and the
uropathologist were blinded to the results of the individ-
ual components of the study. Histopathology reports
were used as reference to perform statistical calculations
where possible. The reports composed of dimensions,
location and characteristics of renal and extra-renal
lesions. Sensitivity, specificity, positive predictive value
and negative predictive value were calculated using SPSS
(IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 22.0. Armonk), and presented as
95 % confidence intervals (CI).
Results
Patient characteristics
Between August 2015 and January 2016, ten consecutive
patients with metastatic lesions and renal tumour were
enrolled into the study (Table 1). All patients underwent
standard imaging such as CT with or without MRI/US/
BS (Additional file 1: Table S1). All ten patients were
males, with the median age of 57 ± 12.2 years. Most
patients had a large primary tumour with the median
size of 7.8 ± 4.3 cm.
Computed tomography
Using CT of the chest and abdomen, 89 lesions were
identified overall (78 extra-renal lesions). Thirty-two
CT-identified lesions were surgically removed or biop-
sied for histopathological correlation. Of the lesions, 24
were consistent with renal cell carcinoma (Additional
file 1: Table S1). The diagnostic values calculated from
histological samples were as follows: sensitivity 68.6 %
(95 % CI 51–83 %) and positive predictive value (PPV)
80 % (95 % CI 61–92 %). When resected samples were
considered as true negatives (e.g. non-pathological
adrenal gland, regional lymph nodes or biopsy sample),
specificity and negative predictive value (NPV) were
88.46 % (95 % CI 76–95 %) and 80.70 % (95 % CI 68–
90 %), respectively (Table 2). The findings were consist-
ent with the current literature [19]. Two of the ten
patients did not receive contrast due to severe renal im-
pairment from large renal tumours and obstructing IVC
thrombi, limiting the efficacy of CT.
PSMA PET
There were 86 PSMA PET abnormalities reported as pri-
mary or metastatic lesions. Histological correlation was
available for 36 of these lesions with 35 of these demon-
strating renal cell carcinoma deposits, whilst 1 biopsy of
pancreatic tail lesion was found to be inconclusive. For
the histologically confirmed lesions, there were no false-
negative PSMA PET lesions; however, CT was false
negative in 11. In the primary lesion, average maximum
standardized uptake value (SUVmax) was 18.0 (range
3.7–36.5), whilst the average SUVmax for metastatic foci
was 19.5 (range 1.5 to ±48). For patient 5 with papillary
RCC, primary and renal vein thrombus SUVmax were
lower than in others at 3.6 and 5.1, respectively. In
patient 3 with ccRCC and sarcomatoid differentiation,
primary tumour SUVmax was 28.6. In patient 7 with un-
classified RCC, primary tumour SUVmax was 18.3.
PSMA PET led to alteration in patients’ management
In one patient (Fig. 1—subject 2), a small liver metastatic
lesion was identified with PSMA PET that was not re-
vealed on non-contrast MRI, US or CT. The patient was
recorded to have previous contrast and gadolinium
reaction, and had non-contrast MRI of the abdomen and
liver, which limited the benefits of CT or MRI. The pa-
tient underwent subsequent cytoreductive nephrectomy
and hemihepatectomy (with histological confirmation of
Table 1 Patient characteristics
Characteristics Parameters
Male/female 10:0
Age—median 57 ± 12.2 years
Primary tumour
size—median
78.3 ± 42.6 mm
Regional lymph nodes
on CT/MRI
n = 3 (30 %)
Pulmonary lesions on
CT/chest X-ray
n = 6 (60 %)





T2: n = 2
T3: n = 5
T4: n = 3
Lymph
node
N0: n = 8
N1: n = 2
Metastasis
M0: n = 5
M1: n = 5
Final histopathology 8 clear cell RCC
1 papillary
1 unclassified
Abbreviations: BS bone scan, CT computed tomography, M metastasis, MRI
magnetic resonance imaging, n number, N lymph node, RCC renal cell
carcinoma, T tumour
Table 2 Diagnostic values of CT and PSMA PET
CT PSMA PET
Lesions detected 89 86
Sensitivity 68.6 % (CI 0.51–0.83) 92.11 % (CI 0.78–0.98)
Positive predictive value 80 % (CI 0.61–0.92) 97.22 % (CI 0.84–1.00)
Positive likelihood ratio 3 (1.59–5.65) 35 (5.06–241.94)














Abbreviations: CT computed tomography, M metastasis, n number, N lymph node,
PSMA prostate-specific membrane antigen, RCC renal cell carcinoma, T tumour
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the liver metastasis). In subject 1 (Fig. 2), bland tumour
was demonstrated in inferior vena cava below tumour
thrombus that was highly PET avid. At the same time,
there was an extension of tumour thrombus into lumber
vein that was identified on PET only. The bland
thrombus was transected below viable tumour, and the
viable tumour with lumbar vein thrombus was excised
using PET imaging as the guide (with histological con-
firmation of tumour involvement corresponding to the
PET abnormality).
Discussion
In this pilot study, we have compared the diagnostic
value of PSMA PET with conventional imaging such as
CT in patients with metastatic RCC. In comparing the
results of imaging to the histopathological reference
from surgical excisional or biopsy samples, PSMA PET
appears to provide comparable sensitivity and PPV over
standard imaging modalities. It resulted in two patients
having treatment modified based on the results. More-
over, it has the advantage of being able to be used in pa-
tients with renal impairment or contrast allergy where
the administration may be contraindicated.
The greatest advantage of PSMA PET over standard
CT is its ability to identify small lesions or lesions in
areas where visualization is difficult such as in the liver
especially when contrast cannot be used. According to
the RECIST criteria 1.1, the dimensions of a malignant
lymph node is defined as a node greater than 15 mm in
short axis depending on the parts of the abdomen and
pelvis [17]. Using PSMA PET, the smallest node identi-
fied was 6 mm with SUVmax of 3.1. Similarly, within
the lung fields, we identified 34 lung lesions with the
average short axis of 9.6 mm and SUVmax of 4.6. Unfor-
tunately, there was only 1 histopathological sample from
the lung fields available for correlation. Being able to
identify sub-centimetre lesions may be important for pa-
tients with true oligometastatic disease or those with
Fig. 1 Comparison of non-contrast CT, MRI and PSMA PET in subject 2. a Non-contrast CT or c non-contrast T1 sequence of MRI did not reveal a lesion in
the right lobe of the liver. On b and d which are PSMA PET images, a focal liver lesion was identified with SUVmax of 15.3 and dimensions of 17 × 13 ×
14 mm. d Fused PET and CT images. The patient had moderate renal impairment and contrast allergy, prohibiting intravenous contrast with MRI or CT
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planned cytoreductive nephrectomy where the adjacent
tumour deposits may be removed at the same time. In
addition, lesions found outside surgical fields may be tar-
geted using stereotactic ablative radiotherapy.
The evidence for using PSMA expression in the neo-
vasculature of renal cell carcinoma deposits for imaging
has been building recently. In a recent case series by
Sawicki et al., the authors demonstrated in six patients the
ability of 68Ga PSMA ligand and PET to detect metastatic
lesion with high contrast; however, overall SUVmax was
substantially lower in primary disease (0.2 ± 0.3) [20].
Using another PSMA-targeting ligand 18F-DCFPyL, Rowe
et al. demonstrated superiority of the ligand over conven-
tional imaging with similar sensitivity (94.7 %) in five
patients [14]. Further, Gorin and Rowe et al. followed up
the findings with the results from a rapid autopsy where
seven of eight sites of radiotracer uptake that was not
demonstrated on contrast enhanced CT were biopsied
and confirmed to be positive for ccRCC.
PSMA is a functional enzyme that may have a role in
developing neovasculature in solid tumours. Rowe et al.,
therefore, also considered the utility of SUVmax calcula-
tions in lesions as a prognostic indicator of response to
systemic therapy such as tyrosine kinase inhibitors
(TKI). For example, metastatic clear cell RCC patients
are more likely to respond to TKI than with another
subtype of RCC that are less likely to express PSMA.
Using the same ligand, Gorin et al. performed a rapid
autopsy after administration and found that all 98 % of
CT-characterized lesions from a patient with metastatic
disease were visualized on PET/CT with 12 further
lesions being found. All histologically proven sites of
ccRCC demonstrated PSMA expression [15]. Another
ligand of interest is indium-111-labelled J591 anti-PSMA
antibody. Pandit-Taskar et al. recently published the re-
sults of 5 case series of patients with metastatic RCC
and 15 with other types of solid tumours in phase I clin-
ical trial [21]. In the study, nodal lesion detection rate
was 66 % in patients with metastatic RCC.
The current study aims to determine the clinical benefits
of PSMA PET over standard imaging in patients with meta-
static renal cell carcinoma. The study was limited in that
not all the suspected metastatic lesions on CT and PET
underwent histologic confirmation. Removing PET avid le-
sions selectively during surgery has introduced selection
bias to the calculation of diagnostic values, and it is one of
the major flaws of the study. Further, no reference standard
for PET or CT negative lesions was used. Nevertheless,
over one third of the suspected lesions had histologic con-
firmation and 11 out of 36 of these were false negative on
Fig. 2 Comparison of CT, MRI and PSMA PET in subject 1. a Contrast CT demonstrates large renal lesion with IVC thrombus extending down to
bilateral lower limbs. b PSMA PET demonstrates avidity within primary tumour and tumour thrombus down to the level of bland thrombus
(red arrow). c MRI showing tumour within IVC, surrounded by bland thrombus. d Axial PSMA PET demonstrates tumour thrombus extending into
the lumbar vein, which was not identified by other imaging modalities—blue arrow
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CT imaging (with no false negatives on PET). In two pa-
tients, contrast CT was unable to be used due to renal im-
pairment, potentially favouring the outcomes of PSMA
PET in these cases.
It is also worth noting that PSMA expression is not
specific to prostate or ccRCC. Therefore, caution must
be exercised in interpreting the results in those with
dual pathologies. Further, due to urinary excretion of
68Ga and PSMA expression in proximal tubules of
kidney, there is limitation in using PSMA PET for detection
and characterization of primary renal tumours.
Conclusions
This pilot study has demonstrated that PSMA PET may
potentially have a role in the preoperative staging of ad-
vanced renal cell carcinoma as PET detected multiple his-
tologically proven metastatic lesions which were false
negative on CT scanning. Surgical strategy was changed in
two patients based on PSMA PET results, with the PET
results subsequently confirmed as true positive. We cau-
tiously support a larger study to confirm these results and
to assess the longitudinal impact on patient outcomes.
Additional file
Additional file 1: Table S1. Results of radiological imaging. (DOC 41 kb)
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